FDA Warns Drug Maker For Minimizing Risk of Brain Infection from Tysabri

Federal regulators have cited Biogen Idec, Inc. for attempting to downplay the risks of a rare, but often fatal, brain infection that has been linked to the multiple sclerosis drug Tysabri. 

The FDA sent a warning letter (pdf) to the company on March 25, accusing the company of misleading statements made in a series of webcasts used to promote Tysabri. According to the FDA, Biogen aired the webcast eight times between late October and early November of 2009.

In the webcasts, the FDA says Biogen played down the risk of contracting progressive mutifocal luekoencephalopathy (PML), which is a serious infection in the brain that can be caused by side effects of Tysabri. In addition, the FDA said that the webcasts failed to inform the viewer of Tysabri’s approved uses.

Did You Know?

Change Healthcare Data Breach Impacts Millions of Customers

A massive Change Healthcare data breach exposed the names, social security numbers, medical and personal information of potentially 100 million Americans, which have now been released on the dark web. Lawsuits are being pursued to obtain financial compensation.

Learn More

Tysabri (natalizumab) is an intravenous injection given every 28 days to treat MS and Crohn’s Disease. Manufactured by Biogen Idec Inc. and marketed with Elan Corp PLC, Tysabri has been shown to prevent relapse, cognitive decline and vision loss associated with MS. Sales of Tysabri bring in about $1 billion annually.

A Tysabri recall was issued in 2005 after three users developed the rare and life-threatening brain infection, which attacks the central nervous system, damaging and inflaming the white matter areas of the brain. The drug was reintroduced in July 2006 with stronger warnings about the potential risk of a PML brain infection from Tysabri and the drug was only made available under strict usage guidelines.

PML is believed to be caused by the common JC virus, and Tysabri may reduce the ability of the immune system to combat the virus. There have been 31 cases of Tysabri brain infections since the drug was reintroduced.

In February, the FDA issued a Tysabri PML warning saying that it now appears that the risk of developing PML increases with the number of Tysabri infusions patients receive.

“We are particularly concerned with this webcast because it presents numerous statements that seriously minimize the risk of PML,” the FDA said in its warning letter. “This presentation misleadingly implies that Tysabri patients who developed PML and received treatment…experienced lessened effects of PML and that patient outcomes will necessarily be improved if Tysabri treatment is stopped at the first sign of PML; this has not been established.”

The FDA said that, in truth, no one knows if early detection of PML or discontinuing use of Tysabri once it’s been detected will mitigate the disease. The FDA also points out that there is no evidence that plasma exchanges, a treatment touted in the webcasts, have any benefit in treating PML or other opportunistic infections.

2 Comments

  • BeckyMay 12, 2010 at 10:19 pm

    My 31 year old son has been on Tysabri for 15 months and is being closely monitored by his doctor and staff. Since on Tysabri, he has had no new lesions but he has had exaserbations with existing. I can only pray that he has no unforeseen issue's, since the other drugs he tried did not work. If I understand correctly, there are only 8-9 hundred people on Tysabri nationwide. My prayers go out [Show More]My 31 year old son has been on Tysabri for 15 months and is being closely monitored by his doctor and staff. Since on Tysabri, he has had no new lesions but he has had exaserbations with existing. I can only pray that he has no unforeseen issue's, since the other drugs he tried did not work. If I understand correctly, there are only 8-9 hundred people on Tysabri nationwide. My prayers go out to everyone suffering with this disease. Of course, I pray daily for a cure, but continued research for safer and more effective drugs is a must. I worry so much about him, especially when the side effects of these drugs, like Tysabri, can ultimately be worse than the disease itself.

  • LisaApril 8, 2010 at 5:59 pm

    Just a minor correction to your post. There have been 42 reported cases of PML in patients using Tysabri.

Share Your Comments

I authorize the above comments be posted on this page*

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

More Top Stories

Lawyers Propose MDL Trial Dates for Baby Formula NEC Lawsuit Starting in May 2025
Lawyers Propose MDL Trial Dates for Baby Formula NEC Lawsuit Starting in May 2025 (Posted yesterday)

A series of four bellwether claims in the baby formula NEC lawsuit MDL will be ready to go before a federal juries in May 2025, August 2025, November 2025 and February 2026 according to a proposed trial schedule agreed upon by both plaintiffs and defendants.

AngioDynamics Port Catheter Lawsuit MDL Established in Southern District of California
AngioDynamics Port Catheter Lawsuit MDL Established in Southern District of California (Posted 2 days ago)

U.S. JPML has transferred all AngioDynamics port catheter lawsuits to the U.S. District Court for the Southern District of California, for coordinated discovery and pretrial proceedings as part of a federal MDL (multidistrict litigation).